JP4960632B2 - 免疫ミルク組成物を有効成分とする単純ヘルペスウイルス感染症治療予防用組成物 - Google Patents
免疫ミルク組成物を有効成分とする単純ヘルペスウイルス感染症治療予防用組成物 Download PDFInfo
- Publication number
- JP4960632B2 JP4960632B2 JP2006002833A JP2006002833A JP4960632B2 JP 4960632 B2 JP4960632 B2 JP 4960632B2 JP 2006002833 A JP2006002833 A JP 2006002833A JP 2006002833 A JP2006002833 A JP 2006002833A JP 4960632 B2 JP4960632 B2 JP 4960632B2
- Authority
- JP
- Japan
- Prior art keywords
- composition
- herpes
- milk
- simplex virus
- herpes simplex
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000008267 milk Substances 0.000 title claims description 59
- 210000004080 milk Anatomy 0.000 title claims description 59
- 235000013336 milk Nutrition 0.000 title claims description 58
- 239000000203 mixture Substances 0.000 title claims description 52
- 208000009889 Herpes Simplex Diseases 0.000 title claims description 35
- 239000004480 active ingredient Substances 0.000 title claims description 8
- 235000020183 skimmed milk Nutrition 0.000 claims description 33
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 claims description 20
- 241000700584 Simplexvirus Species 0.000 claims description 16
- 241000124008 Mammalia Species 0.000 claims description 14
- 108010046377 Whey Proteins Proteins 0.000 claims description 12
- 102000007544 Whey Proteins Human genes 0.000 claims description 12
- 235000013365 dairy product Nutrition 0.000 claims description 12
- 239000000126 substance Substances 0.000 claims description 12
- 241000283690 Bos taurus Species 0.000 claims description 10
- 239000012141 concentrate Substances 0.000 claims description 9
- 230000002163 immunogen Effects 0.000 claims description 8
- 235000021119 whey protein Nutrition 0.000 claims description 7
- 241000194017 Streptococcus Species 0.000 claims description 6
- 239000002994 raw material Substances 0.000 claims description 6
- 208000003265 stomatitis Diseases 0.000 claims description 6
- 239000005862 Whey Substances 0.000 claims description 5
- 206010010741 Conjunctivitis Diseases 0.000 claims description 4
- 201000009906 Meningitis Diseases 0.000 claims description 4
- 201000004946 genital herpes Diseases 0.000 claims description 4
- 206010023332 keratitis Diseases 0.000 claims description 4
- 241000283707 Capra Species 0.000 claims description 3
- 208000001688 Herpes Genitalis Diseases 0.000 claims description 3
- 208000004898 Herpes Labialis Diseases 0.000 claims description 3
- 208000000903 Herpes simplex encephalitis Diseases 0.000 claims description 3
- 102000014171 Milk Proteins Human genes 0.000 claims description 3
- 108010011756 Milk Proteins Proteins 0.000 claims description 3
- 206010067152 Oral herpes Diseases 0.000 claims description 3
- 241001494479 Pecora Species 0.000 claims description 3
- 235000021239 milk protein Nutrition 0.000 claims description 3
- 241000283086 Equidae Species 0.000 claims description 2
- 241000588769 Proteus <enterobacteria> Species 0.000 claims description 2
- 241000194019 Streptococcus mutans Species 0.000 claims description 2
- 241000193998 Streptococcus pneumoniae Species 0.000 claims description 2
- 230000007170 pathology Effects 0.000 claims description 2
- 229940031000 streptococcus pneumoniae Drugs 0.000 claims description 2
- 241000606768 Haemophilus influenzae Species 0.000 claims 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 claims 1
- 241001354013 Salmonella enterica subsp. enterica serovar Enteritidis Species 0.000 claims 1
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 claims 1
- 241000191940 Staphylococcus Species 0.000 claims 1
- 241000194024 Streptococcus salivarius Species 0.000 claims 1
- 229940047650 haemophilus influenzae Drugs 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 230000000638 stimulation Effects 0.000 description 58
- 230000035622 drinking Effects 0.000 description 49
- 239000000427 antigen Substances 0.000 description 33
- 102000036639 antigens Human genes 0.000 description 33
- 108091007433 antigens Proteins 0.000 description 33
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 27
- 239000000843 powder Substances 0.000 description 24
- 238000004519 manufacturing process Methods 0.000 description 22
- 102100037850 Interferon gamma Human genes 0.000 description 21
- 108010074328 Interferon-gamma Proteins 0.000 description 21
- 241000700588 Human alphaherpesvirus 1 Species 0.000 description 18
- 241000701074 Human alphaherpesvirus 2 Species 0.000 description 17
- 230000000694 effects Effects 0.000 description 15
- 210000004027 cell Anatomy 0.000 description 14
- 230000002265 prevention Effects 0.000 description 14
- 238000006243 chemical reaction Methods 0.000 description 13
- 241000700605 Viruses Species 0.000 description 12
- 208000024891 symptom Diseases 0.000 description 12
- 108060003951 Immunoglobulin Proteins 0.000 description 10
- 102000018358 immunoglobulin Human genes 0.000 description 10
- 230000001575 pathological effect Effects 0.000 description 10
- 230000003716 rejuvenation Effects 0.000 description 9
- 230000035584 blastogenesis Effects 0.000 description 7
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 7
- 238000012545 processing Methods 0.000 description 7
- 208000015181 infectious disease Diseases 0.000 description 6
- 210000004698 lymphocyte Anatomy 0.000 description 6
- 238000005259 measurement Methods 0.000 description 6
- 238000007796 conventional method Methods 0.000 description 5
- 235000013305 food Nutrition 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 4
- 244000052616 bacterial pathogen Species 0.000 description 4
- 239000005018 casein Substances 0.000 description 4
- 235000013861 fat-free Nutrition 0.000 description 4
- 210000000987 immune system Anatomy 0.000 description 4
- 230000036039 immunity Effects 0.000 description 4
- 229940104230 thymidine Drugs 0.000 description 4
- 230000007704 transition Effects 0.000 description 4
- 108010076119 Caseins Proteins 0.000 description 3
- 102000011632 Caseins Human genes 0.000 description 3
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 3
- 230000000890 antigenic effect Effects 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 3
- 235000021240 caseins Nutrition 0.000 description 3
- 201000005884 exanthem Diseases 0.000 description 3
- 229940072221 immunoglobulins Drugs 0.000 description 3
- 230000002458 infectious effect Effects 0.000 description 3
- 210000005259 peripheral blood Anatomy 0.000 description 3
- 239000011886 peripheral blood Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 206010037844 rash Diseases 0.000 description 3
- 229910052722 tritium Inorganic materials 0.000 description 3
- 229960005486 vaccine Drugs 0.000 description 3
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 102000010445 Lactoferrin Human genes 0.000 description 2
- 108010063045 Lactoferrin Proteins 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- 229960004150 aciclovir Drugs 0.000 description 2
- MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 description 2
- 239000003443 antiviral agent Substances 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 2
- 235000013361 beverage Nutrition 0.000 description 2
- 229960000074 biopharmaceutical Drugs 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 2
- 230000003308 immunostimulating effect Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 description 2
- 235000021242 lactoferrin Nutrition 0.000 description 2
- 229940078795 lactoferrin Drugs 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 208000020154 Acnes Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 208000007514 Herpes zoster Diseases 0.000 description 1
- 102000004407 Lactalbumin Human genes 0.000 description 1
- 108090000942 Lactalbumin Proteins 0.000 description 1
- 102100033468 Lysozyme C Human genes 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 206010033733 Papule Diseases 0.000 description 1
- 108010001441 Phosphopeptides Proteins 0.000 description 1
- 108010047620 Phytohemagglutinins Proteins 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 241000282849 Ruminantia Species 0.000 description 1
- 241000607768 Shigella Species 0.000 description 1
- HDOVUKNUBWVHOX-QMMMGPOBSA-N Valacyclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCOC(=O)[C@@H](N)C(C)C)C=N2 HDOVUKNUBWVHOX-QMMMGPOBSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 210000001099 axilla Anatomy 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- -1 brighteners Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 108010067454 caseinomacropeptide Proteins 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 210000003022 colostrum Anatomy 0.000 description 1
- 235000021277 colostrum Nutrition 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 235000015140 cultured milk Nutrition 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 206010014599 encephalitis Diseases 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 235000021105 fermented cheese Nutrition 0.000 description 1
- 239000012997 ficoll-paque Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 210000004195 gingiva Anatomy 0.000 description 1
- 239000003365 glass fiber Substances 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000007124 immune defense Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 229960001438 immunostimulant agent Drugs 0.000 description 1
- 239000003022 immunostimulating agent Substances 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 150000003833 nucleoside derivatives Chemical class 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 235000014593 oils and fats Nutrition 0.000 description 1
- 238000009928 pasteurization Methods 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 210000003899 penis Anatomy 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 230000001885 phytohemagglutinin Effects 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 235000021067 refined food Nutrition 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 210000004706 scrotum Anatomy 0.000 description 1
- 230000009758 senescence Effects 0.000 description 1
- 230000001235 sensitizing effect Effects 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 238000009281 ultraviolet germicidal irradiation Methods 0.000 description 1
- 229940093257 valacyclovir Drugs 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 210000003857 wrist joint Anatomy 0.000 description 1
- 235000020125 yoghurt-based beverage Nutrition 0.000 description 1
- 235000013618 yogurt Nutrition 0.000 description 1
Description
大谷等 機能性食品と薬理栄養 Vol. 2, No. 4 (2005) p241-247
免疫ミルク組成物として、米国ストール ミルク バイオロジクス社製の脱脂粉乳(商品名;「スターリミルク」(兼松ウェルネス株式会社から販売))を用いて以下の試験を行った。なお、前記脱脂粉乳は、上記表1に示す26種類の病原菌由来の抗原物質で感作した乳牛から採取した乳から、常法にしたがって調製した脱脂粉乳であり、飲用1回分の20〜40g当たりに96〜192mgの免疫グロブリン(IgG)を含む。
以下の試験においては、25名のボランティア被験者に上記1回分20g(1名については40g)の脱脂粉乳を水又はお湯に溶かして1日1回1年間飲用してもらい、その飲用による単純ヘルペスウイルス感染による症状の改善効果及び単純ヘルペスに対する特異的な免疫増強効果について調べた。ボランティア被験者は、男性15名、女性10名で、平均年齢56歳(男61歳、女48歳)であり、そのうち、男性13名、女性7名についてはHSV抗体陽性者であり、その他は、HSV抗体陰性者であった。また、そのうち、男性12名、女性5名は、手指、体幹四肢、口唇、顔、鼻口唇、手関節、全身、陰嚢、ペニス、両腋窩、体幹、手背を患部とする皮疹の症状のある北里大学病院皮膚科の外来患者であり、そのうち2名はアシクロビルを有効成分とする「ゾビラックス」(商品名、塩野義製薬株式会社製)の服用者であった。これらボランティア被験者の内訳を表2に示す。なお、上記脱脂粉乳の1年間の飲用試験において有害事象はなかった。また、試験期間中3ヶ月おきに、上記25名の被験者の一般血液検査(末梢血血算、生化学及び免疫グロブリンGAM)を実施したが、飲用前に比しての異常値は見られず、身体の一般的な免疫力に変化がないことを確認した。
以下の試験においては、上記脱脂粉乳の飲用が単純ヘルペスに対する特異的な免疫増強効果を与えるかについて調べた。
HSV特異的抗原、あるいはPHAを刺激因子とする末梢血リンパ球からのIFN―γ産生について、それが上記脱脂粉乳の飲用によってどのように影響されるかを調べた。すなわち、上記と同様にして脱脂粉乳の飲用開始前と12ヶ月飲用後の被験者の全血から調製した末梢血リンパ球を含む末梢血単核球(PBMC)を用いて、末梢血リンパ球からのIFN―γ産生量を調べた。
上記脱脂粉乳の飲用開始前と12ヶ月飲用後の被験者の末梢血中のHSV特異的IgG抗体価を、常法に従い、HSV-1及びHSV-2の双方に特異的に結合する抗体を用いたELISA法により測定した。その結果を図7に示す。
上記(1)末梢血リンパ球幼若化に及ぼす影響、及び、(2)IFN―γ産生に及ぼす影響について、HSV抗体陰性者における上記脱脂粉乳の飲用開始前と12ヶ月飲用後の結果を抽出して図8〜9に示す。
以上(2)〜(5)の結果を下記表3にまとめて示す。
Claims (3)
- 単純ヘルペスウイルスを原因とする病態を治療し及び/又は予防するために用いられる組成物であって、免疫ミルク組成物を有効成分として含有し、該免疫ミルク組成物は、スタフィロコッカス シムランス、スタフィロッコカス エビデルミディス、ストレプトコッカス ビオゲネス、アエロバクター アイロゲネス、エシィリキア コリ、サルモネラ エンテリティディス、シュードモナス エルギノーザ、クレブジェラ ニューモニエ、サルモネラ チフィムリウム、ヘモフィルス インフルエンゼ、ストレプトコッカス ミチス、プロテウス ブルガリカス、シゲラ ディセンテリエ、プロピオバクテリウム アクネス、ストレプトコッカス サングイス、ストレプトコッカス サリバリウス、ストレプトコッカス ミュータンス、ストレプトコッカス アガラクチエ、及びストレプトコッカス ニューモニエを含む免疫原性物質で感作した哺乳動物から搾乳した乳又は該乳を原料とする乳加工組成物であり、前記単純ヘルペスウイルスを原因とする病態が、ヘルペス性角膜炎、ヘルペス性結膜炎、ヘルペス性髄膜炎、ヘルペス性脳炎、ヘルペス性口内炎、ヘルペス性歯肉口内炎、口唇ヘルペス、性器ヘルペス又は新生児ヘルペスであることを特徴とする単純ヘルペスウイルス感染症治療予防用組成物。
- 前記乳加工組成物が、脱脂乳、脱脂粉乳、乳清、乳清たんぱく質濃縮物、又は乳たんぱく質濃縮物である請求項1記載の単純ヘルペスウイルス感染症治療予防用組成物。
- 前記哺乳動物が、ウシ、ヤギ、ヒツジ、又はウマから選ばれた少なくとも1種である請求項1又は2に記載の単純ヘルペスウイルス感染症治療予防用組成物。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2006002833A JP4960632B2 (ja) | 2006-01-10 | 2006-01-10 | 免疫ミルク組成物を有効成分とする単純ヘルペスウイルス感染症治療予防用組成物 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2006002833A JP4960632B2 (ja) | 2006-01-10 | 2006-01-10 | 免疫ミルク組成物を有効成分とする単純ヘルペスウイルス感染症治療予防用組成物 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2007182408A JP2007182408A (ja) | 2007-07-19 |
JP4960632B2 true JP4960632B2 (ja) | 2012-06-27 |
Family
ID=38338787
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2006002833A Active JP4960632B2 (ja) | 2006-01-10 | 2006-01-10 | 免疫ミルク組成物を有効成分とする単純ヘルペスウイルス感染症治療予防用組成物 |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP4960632B2 (ja) |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE448344B (sv) * | 1978-02-06 | 1987-02-16 | Stolle Res & Dev | Antikropp for behandling av reumatoid artrit samt sett att framstella denna |
JP3057300B2 (ja) * | 1991-03-12 | 2000-06-26 | エーザイ株式会社 | 加齢に伴う免疫機能低下を抑制する組成物 |
IE970541A1 (en) * | 1997-07-25 | 1999-01-27 | Michael Anthony Folan | Maternal immune secretions and their use in the treatment and/or prophylaxis of the buccal cavity |
AU6726500A (en) * | 1999-08-24 | 2001-03-19 | Nomoto, Kikuo | Methods of pasteurizing immune substance containing antiinflammatory factor and utilization thereof |
-
2006
- 2006-01-10 JP JP2006002833A patent/JP4960632B2/ja active Active
Also Published As
Publication number | Publication date |
---|---|
JP2007182408A (ja) | 2007-07-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Uruakpa et al. | Colostrum and its benefits: a review | |
Shinkai et al. | Immunoprotective effects of oral intake of heat-killed Lactobacillus pentosus strain b240 in elderly adults: a randomised, double-blind, placebo-controlled trial | |
US6852700B1 (en) | Colostrinin, and uses thereof | |
KR100297959B1 (ko) | 유장단백질로hiv-혈청양성개체의치료방법 | |
Narayanan et al. | A planned prospective evaluation of the anti‐infective property of varying quantities of expressed human milk | |
Satyaraj et al. | Supplementation of diets with bovine colostrum influences immune function in dogs | |
Wong et al. | Bovine colostrum enhances natural killer cell activity and immune response in a mouse model of influenza infection and mediates intestinal immunity through toll-like receptors 2 and 4 | |
EA016039B1 (ru) | Способы ухода за лактирующими животными и фармацевтические композиции, используемые для их осуществления | |
Núnez et al. | Effect of a probiotic fermented milk on the thymus in Balb/c mice under non-severe protein–energy malnutrition | |
JP2002501526A (ja) | 乳汁における免疫グロブリンaの生成方法 | |
Ren et al. | Isoleucine attenuates infection induced by E. coli challenge through the modulation of intestinal endogenous antimicrobial peptide expression and the inhibition of the increase in plasma endotoxin and IL-6 in weaned pigs | |
FR2537436A1 (fr) | Procede de regulation de l'appetit et de l'efficacite de l'utilisation des aliments utilisant de l'interferon | |
Linehan et al. | Bovine Colostrum for Veterinary and Human Health Applications: A Critical Review | |
Hung et al. | Hyperimmune colostrum alleviates rheumatoid arthritis in a collagen-induced arthritis murine model | |
EP0102831A1 (en) | Production of antibodies | |
Biswas et al. | Immunomodulatory effects of bovine colostrum in human peripheral blood mononuclear cells | |
Bullen | Iron‐binding proteins and other factors in milk responsible for resistance to Escherichia coli | |
Dupont | Donor milk compared with mother’s own milk | |
Porter | Structural and functional characteristics of immunoglobulins of the common domestic species | |
EP0914831B1 (en) | Biological product for preventive or therapeutic oral administration against canine parvovirosis | |
JP4960632B2 (ja) | 免疫ミルク組成物を有効成分とする単純ヘルペスウイルス感染症治療予防用組成物 | |
Anwar et al. | Immune potentiating role of protein, probiotic and symbiotic supplementation in moulted White Leghorn hens | |
WO2009074539A1 (en) | Prevention and treatment of otitis media using iga enriched milk | |
US10478493B2 (en) | Method of treating protozoal gastrointestinal disorders in immunocompromised patients | |
Rigo-Adrover et al. | 30. Whey protein is beneficial for rotavirus-induced diarrhoea in preclinical studies |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20090109 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20090109 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20111220 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120220 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20120313 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20120323 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20150330 Year of fee payment: 3 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 4960632 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
S531 | Written request for registration of change of domicile |
Free format text: JAPANESE INTERMEDIATE CODE: R313531 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |